Allogene licensor Cellectis faces patent case (ALLO:NASDAQ)

Core Viewpoint - Allogene Therapeutics announced that its licensor, Cellectis, is facing a lawsuit in the U.S. regarding patent infringement related to gene editing technology [2] Company Summary - Allogene Therapeutics is involved in the development of cancer drugs and is impacted by the legal issues surrounding its licensor, Cellectis [2] - The lawsuit could have implications for Allogene's operations and its relationship with Cellectis, which is crucial for its gene editing technology [2] Industry Summary - The gene editing technology sector is facing legal challenges that may affect companies involved in this field, highlighting the importance of intellectual property rights [2]